tetano
Editor, Senior Moderator
J Infect Dis
. 2021 Mar 4;jiab124.
doi: 10.1093/infdis/jiab124. Online ahead of print.
Longitudinal assessment of anti-SARS-CoV-2 immune responses for six months based on the clinical severity of COVID-19
Ji Yun Noh[SUP] 1 [/SUP], Jeong-Eun Kwak[SUP] 2 [/SUP], Jeong-Sun Yang[SUP] 3 [/SUP], Soon Young Hwang[SUP] 4 [/SUP], Jin Gu Yoon[SUP] 1 [/SUP], Hye Seong[SUP] 1 [/SUP], Hakjun Hyun[SUP] 1 [/SUP], Chae Seung Lim[SUP] 5 [/SUP], Soo-Young Yoon[SUP] 5 [/SUP], Jungsang Ryou[SUP] 3 [/SUP], Joo-Yeon Lee[SUP] 3 [/SUP], Sung-Soon Kim[SUP] 3 [/SUP], Su-Hyung Park[SUP] 2 6 [/SUP], Hee Jin Cheong[SUP] 1 [/SUP], Woo Joo Kim[SUP] 1 [/SUP], Eui-Cheol Shin[SUP] 2 6 [/SUP], Joon Young Song[SUP] 1 [/SUP]
Affiliations
Abstract
There is insufficient data on the longevity of immunity acquired following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We aimed to evaluate the duration of SARS-CoV-2-specific humoral and cellular immunity according to the clinical severity of coronavirus disease 2019 (COVID-19). The study population comprised asymptomatic (n=14), symptomatic/non-pneumonic (n=42), and pneumonic (n=41) patients. The anti-SARS-CoV-2 IgG and neutralizing antibody (NAb) titers lasted until six months after diagnosis, with positivity rates of 66.7% and 86.9%, respectively. Older age, prolonged viral shedding and accompanying pneumonia were more frequently found in patients with sustained humoral immunity. SARS-CoV-2 specific T-cell response was strongly observed in pneumonic patients and prominent in individuals with sustained humoral immunity. In conclusion, most (> 85%) patients carries NAb until six months after diagnosis of SARS-CoV-2 infection, providing insights for establishing vaccination strategies against COVID-19.
Keywords: COVID-19; SARS-CoV-2; cellular immunity; humoral immunity; longevity.
. 2021 Mar 4;jiab124.
doi: 10.1093/infdis/jiab124. Online ahead of print.
Longitudinal assessment of anti-SARS-CoV-2 immune responses for six months based on the clinical severity of COVID-19
Ji Yun Noh[SUP] 1 [/SUP], Jeong-Eun Kwak[SUP] 2 [/SUP], Jeong-Sun Yang[SUP] 3 [/SUP], Soon Young Hwang[SUP] 4 [/SUP], Jin Gu Yoon[SUP] 1 [/SUP], Hye Seong[SUP] 1 [/SUP], Hakjun Hyun[SUP] 1 [/SUP], Chae Seung Lim[SUP] 5 [/SUP], Soo-Young Yoon[SUP] 5 [/SUP], Jungsang Ryou[SUP] 3 [/SUP], Joo-Yeon Lee[SUP] 3 [/SUP], Sung-Soon Kim[SUP] 3 [/SUP], Su-Hyung Park[SUP] 2 6 [/SUP], Hee Jin Cheong[SUP] 1 [/SUP], Woo Joo Kim[SUP] 1 [/SUP], Eui-Cheol Shin[SUP] 2 6 [/SUP], Joon Young Song[SUP] 1 [/SUP]
Affiliations
- PMID: 33686421
- DOI: 10.1093/infdis/jiab124
Abstract
There is insufficient data on the longevity of immunity acquired following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We aimed to evaluate the duration of SARS-CoV-2-specific humoral and cellular immunity according to the clinical severity of coronavirus disease 2019 (COVID-19). The study population comprised asymptomatic (n=14), symptomatic/non-pneumonic (n=42), and pneumonic (n=41) patients. The anti-SARS-CoV-2 IgG and neutralizing antibody (NAb) titers lasted until six months after diagnosis, with positivity rates of 66.7% and 86.9%, respectively. Older age, prolonged viral shedding and accompanying pneumonia were more frequently found in patients with sustained humoral immunity. SARS-CoV-2 specific T-cell response was strongly observed in pneumonic patients and prominent in individuals with sustained humoral immunity. In conclusion, most (> 85%) patients carries NAb until six months after diagnosis of SARS-CoV-2 infection, providing insights for establishing vaccination strategies against COVID-19.
Keywords: COVID-19; SARS-CoV-2; cellular immunity; humoral immunity; longevity.